Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML) | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02115295

Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML)
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The goal of this clinical research study is to learn if the combination of cladribine, idarubicin, and cytarabine can help to control AML, high risk MDS, and/or CML in blast phase. The safety of these drugs will also be studied.

Status: 
Recruiting
Study Date: 
Thu, 05/01/2014 to Tue, 05/01/2018
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: Cladribine Induction Phase: Cladribine 5 mg/m2/day by vein on Days 1 - 5. Consolidation Phase: Cladribine 5 mg/m2/day by vein on Days 1 - 3. Other Names: Leustatin 2-CdA Drug: Cytarabine Induction Phase: Cytarabine 1 gram/m2/day by vein on Days 1 - 5. Consolidation Phase: Cytarabine 0.75 gram/m2/day by vein on Days 1 - 3. Other Names: Ara-C Cytosar DepoCyt Cytosine Arabinosine Hydrochloride Drug: Idarubicin Induction Phase: Idarubicin 10 mg/m2/day by vein on Days 1 - 3. Consolidation Phase: Idarubicin 8 mg/m2/day by vein on Days 1 - 2. Behavioral: Phone Calls After last dose of study drug, participant called every 6 -12 months by a member of the study staff to ask about any side effects they may be having. The phone call should take about 5-10 minutes.